Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA). Taltz was first approved by the FDA in March 2016 for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Indications: Taltz is a humanized interleukin-17A antagonist indicated for the treatment of adults with active PsA.

Dosage/administration: For PsA, the recommended dose is 160 mg by subcutaneous injection (2 80 mg injections) at week 0, followed by 80 mg every 4 weeks. For PsA patients with coexistent moderate-to-severe plaque psoriasis, refer to the dosing regimen for plaque psoriasis. Taltz may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (DMARD).

Adverse reactions: Most common (≥1%) adverse reactions associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.